GlassScriptPhysician profile
Katherine Moore
NPI 1740834316
$8,686.87
in general payments reported to CMS, 2019-2025
33 companies · $793 in 2025
The $793 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,949 · 2022: $1,885 · 2023: $1,275 · 2024: $1,785 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,707 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,706.94 |
| Education | $145.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,465.83 | 2021-2024 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $1,401.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,274.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $884.49 | 2021-2022 | |
| Amgen INC. | $846.73 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $698.47 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $392.68 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $307.34 | 2021-2022 | |
| Madrigal Pharmaceuticals | $253.90 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.26 | 2021-2025 | Jardiance |
| Abbott Laboratories | $123.81 | 2021-2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $120.53 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.22 | 2021-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $80.82 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $80.67 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $45.69 | 2025 | Simponi Aria, Simponi, Stelara |
| Sunovion Pharmaceuticals INC. | $42.13 | 2022 | |
| Axsome Therapeutics, INC. | $41.19 | 2023 | Auvelity |
| Sumitomo Pharma America, INC. | $40.34 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $38.57 | 2025 | Voquezna |
| Pulmonx Corporation | $35.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.72 | 2025 | Entyvio |
| Ultragenyx Pharmaceutical INC. | $19.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.91 | 2024 | |
| Pfizer INC. | $15.71 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $14.98 | 2021 | |
| Exact Sciences Corporation | $14.64 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $14.09 | 2024 | Contrave |
| Biohaven Pharmaceutical Holding Company LTD. | $13.62 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.32 | 2024 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $11.74 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.64 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.